Budget-friendly retail giant Family Dollar has reportedly adopted a so-called poison pill to protect itself against hostile takeovers as activist investor Carl Icahn considers pushing for a merger with rival Dollar General.
Reports say Family Dollar adopted the plan, which allows the company to dilute shares of investors if they exceed a certain threshold of ownership. The plan was implemented as Icahn, who announced a 9.39 percent ownership in Family Dollar late last week, considers pushing for a merger with top rival Dollar General.
But the “poison pill” only “puts a damper” on what could be a friendly merger dialogue between the two retailers, Icahn said Monday, adding that the company was already planning such a discussion.
According to reports, analysts suggest Dollar General could seek to acquire its competitor as it struggles to compete against Wal-Mart, Target and other low-income retail destinations.
Full content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Turkey Ends Meta Investigation Over Threads and Instagram
Dec 8, 2024 by
CPI
Supreme Court to Hear CCI Petition on Amazon, Flipkart Antitrust Cases
Dec 8, 2024 by
CPI
Senators Urge Antitrust Probe Into FanDuel and DraftKings
Dec 8, 2024 by
CPI
Novo Holdings Secures EU Approval for $16.5 Billion Catalent Acquisition
Dec 8, 2024 by
CPI
US Appeals Court Upholds TikTok Divestment Law, Paving Way for Potential Ban
Dec 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Moats & Entrenchment
Nov 29, 2024 by
CPI
Assessing the Potential for Antitrust Moats and Trenches in the Generative AI Industry
Nov 29, 2024 by
Allison Holt, Sushrut Jain & Ashley Zhou
How SEP Hold-up Can Lead to Entrenchment
Nov 29, 2024 by
Jay Jurata, Elena Kamenir & Christie Boyden
The Role of Moats in Unlocking Economic Growth
Nov 29, 2024 by
CPI
Overcoming Moats and Entrenchment: Disruptive Innovation in Generative AI May Be More Successful than Regulation
Nov 29, 2024 by
Simon Chisholm & Charlie Whitehead